IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Effect of calcitonin on anastrozole-induced bone pain during aromatase inhibitor therapy for breast cancer
Liu, P.; Yang, D. Q.; Xie, F.; Zhou, B.; Liu, M.
关键词Calcitonin Bone Pain Anastrozole Breast Cancer Aromatase Inhibitor
刊名GENETICS AND MOLECULAR RESEARCH
2014
DOI10.4238/2014.July.24.7
13期:3页:5285-5291
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Biochemistry & Molecular Biology ; Genetics & Heredity
资助者Astrazeneca ; Astrazeneca
研究领域[WOS]Biochemistry & Molecular Biology ; Genetics & Heredity
关键词[WOS]POSTOPERATIVE ADJUVANT CHEMOTHERAPY ; PROSTATE-CANCER ; OSTEOPOROSIS ; MANAGEMENT ; EFFICACY ; HORMONE
英文摘要

This study aimed to investigate calcitonin as an effective therapy for osteoporosis in patients with bone pain during the anastrozole treatment of breast cancer. Ninety-one patients, who were on anastrozole treatment for breast cancer and also suffered anastrozole-induced bone pain, were randomly divided into two groups: the calcitonin group received salmon calcitonin and Caltrate D, and the control group received Caltrate D. All patients were evaluated by the visual analogue scale (VAS) and underwent the dual energy x-ray absorptiometry test for bone mineral density (BMD), and serum osteocalcin (BGP), alkaline phosphatase (ALP), calcium (Ca), and phosphorus (P) were measured at three months before and after the treatment. Significant differences in serum Ca, P, BGP, and ALP were found in each group between before and after treatment (P < 0.05), while no differences between the calcitonin and control groups were found. No difference was observed in femur BMD between the two groups, or between before and after treatment in each group. There was a significant difference in spine BMD between before and after treatment in the control group (P < 0.05) but not in the calcitonin group, while no difference was found between the calcitonin and control groups. Futhermore, VAS score significantly declined in each group after treatment (P < 0.05), but much more in the calcitonin group than the control group (P < 0.05). Our finding suggests that calcitonin may alleviate bone pain during the anastrozole treatment of breast cancer but has no effect on bone loss during cancer treatment.

语种英语
资助者Astrazeneca ; Astrazeneca
WOS记录号WOS:000340383600061
引用统计
被引频次:3[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/51472
专题北京大学第二临床医学院
作者单位Peking Univ, Peoples Hosp, Dept Surg IV, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Liu, P.,Yang, D. Q.,Xie, F.,et al. Effect of calcitonin on anastrozole-induced bone pain during aromatase inhibitor therapy for breast cancer[J]. GENETICS AND MOLECULAR RESEARCH,2014,13(3):5285-5291.
APA Liu, P.,Yang, D. Q.,Xie, F.,Zhou, B.,&Liu, M..(2014).Effect of calcitonin on anastrozole-induced bone pain during aromatase inhibitor therapy for breast cancer.GENETICS AND MOLECULAR RESEARCH,13(3),5285-5291.
MLA Liu, P.,et al."Effect of calcitonin on anastrozole-induced bone pain during aromatase inhibitor therapy for breast cancer".GENETICS AND MOLECULAR RESEARCH 13.3(2014):5285-5291.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Liu, P.]的文章
[Yang, D. Q.]的文章
[Xie, F.]的文章
百度学术
百度学术中相似的文章
[Liu, P.]的文章
[Yang, D. Q.]的文章
[Xie, F.]的文章
必应学术
必应学术中相似的文章
[Liu, P.]的文章
[Yang, D. Q.]的文章
[Xie, F.]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。